GSK plc Form 6-K: Report of foreign private issuer
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-12-23: Form 6-K; Period of report 2013-12-23; Description DIRECTOR/PDMR SHAREHOLDING; Document gsk201312236k.htm.
- 2013-12-18: Form 6-K; Period of report 2013-12-18; Description FDA APPROVES ANORO ELLIPTA; Document gsk201312186k.htm.
- 2013-12-17: Form 6-K; Period of report 2013-12-17; Description TRANSACTION IN OWN SHARES; Document gsk201312176k.htm.
- 2013-12-16: Form 6-K; Period of report 2013-12-16; Description TRANSACTION IN OWN SHARES; Document gsk201312166k1.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2013-12-23 | 6-K | 2013-12-23 | DIRECTOR/PDMR SHAREHOLDING | gsk201312236k.htm |
| 2013-12-18 | 6-K | 2013-12-18 | FDA APPROVES ANORO ELLIPTA | gsk201312186k.htm |
| 2013-12-17 | 6-K | 2013-12-17 | TRANSACTION IN OWN SHARES | gsk201312176k.htm |
| 2013-12-16 | 6-K | 2013-12-16 | TRANSACTION IN OWN SHARES | gsk201312166k1.htm |
| 2013-12-16 | 6-K | 2013-12-13 | GSK TO INCREASE STAKE IN ITS INDIAN PHARMA. CO. | gsk201312166k.htm |
| 2013-12-13 | 6-K | 2013-12-13 | TRANSACTION IN OWN SHARES | gsk201312136k.htm |
| 2013-12-12 | 6-K | 2013-12-12 | TRANSACTION IN OWN SHARES | gsk201312126k.htm |
| 2013-12-11 | 6-K | 2013-12-11 | TRANSACTION IN OWN SHARES | gsk201312116k3.htm |
| 2013-12-11 | 6-K | 2013-12-11 | DIRECTOR/PDMR SHAREHOLDING | gsk201312116k2.htm |
| 2013-12-11 | 6-K | 2013-12-11 | DIRECTOR/PDMR SHAREHOLDING | gsk201312116k1.htm |
| 2013-12-11 | 6-K | 2013-12-11 | BOARD COMMITTEE CHANGE | gsk201312116k.htm |
| 2013-12-10 | 6-K | 2013-12-10 | TRANSACTION IN OWN SHARES | gsk201312106k.htm |
| 2013-12-09 | 6-K | 2013-12-09 | TRANSACTION IN OWN SHARES | gsk201312096k1.htm |
| 2013-12-09 | 6-K | 2013-12-09 | DIRECTOR/PDMR SHAREHOLDING | gsk201312096k.htm |
| 2013-12-05 | 6-K | 2013-12-05 | TRANSACTION IN OWN SHARES | gsk201312056k.htm |
| 2013-12-04 | 6-K | 2013-12-04 | TRANSACTION IN OWN SHARES | gsk201312046k.htm |
| 2013-12-03 | 6-K | 2013-12-03 | TRANSACTION IN OWN SHARES | gsk201312036k.htm |
| 2013-12-02 | 6-K | 2013-12-02 | TRANSACTION IN OWN SHARES | gsk201312026k2.htm |
| 2013-12-02 | 6-K | 2013-12-02 | TOTAL VOTING RIGHTS | gsk201312026k.htm |
| 2013-11-29 | 6-K | 2013-11-29 | TRANSACTION IN OWN SHARES | gsk201311296k2.htm |
| 2013-11-29 | 6-K | 2013-11-29 | DIRECTOR/PDMR SHAREHOLDING | gsk201311296k.htm |
| 2013-11-29 | 6-K | 2013-11-28 | TRANSACTION IN OWN SHARES | gsk201311286k.htm |
| 2013-11-27 | 6-K | 2013-11-27 | TRANSACTION IN OWN SHARES | gsk201311276k.htm |
| 2013-11-25 | 6-K | 2013-11-25 | DIRECTOR/PDMR SHAREHOLDING | gsk201311256k.htm |
| 2013-11-22 | 6-K | 2013-11-22 | TIVICAY? (DOLUTEGRAVIR) - POSITIVE CHMP OPINION | gsk201311226k.htm |
| 2013-11-20 | 6-K | 2013-11-20 | GSK COMPLETES PARTIAL SALE OF ASPEN | gsk201311206k2.htm |
| 2013-11-20 | 6-K | 2013-11-20 | GSK INTENDS TO DIVEST PART HOLDING IN ASPEN | gsk201311206k.htm |
| 2013-11-18 | 6-K | 2013-11-18 | DIRECTOR/PDMR SHAREHOLDING | gsk201311186k1.htm |
| 2013-11-18 | 6-K | 2013-11-18 | RELVAR ELLIPTA RECEIVES EC MARKETING AUTHORISATION | gsk201311186k.htm |
| 2013-11-15 | 6-K | 2013-11-15 | BLOCKLISTING INTERIM REVIEW | gsk201311156k2.htm |
| 2013-11-15 | 6-K | 2013-11-15 | DIRECTOR/PDMR SHAREHOLDING | gsk201311156k1.htm |
| 2013-11-15 | 6-K | 2013-11-15 | TRANSACTION IN OWN SHARES | gsk201311156k.htm |
| 2013-11-14 | 6-K | 2013-11-14 | TRANSACTION IN OWN SHARES | gsk201311146k.htm |
| 2013-11-13 | 6-K | 2013-11-13 | TRANSACTION IN OWN SHARES | gsk201311136k.htm |
| 2013-11-12 | 6-K | 2013-11-12 | DIRECTOR/PDMR SHAREHOLDING | gsk201311126k3.htm |
| 2013-11-12 | 6-K | 2013-11-12 | DIRECTOR/PDMR SHAREHOLDING | gsk201311126k2.htm |
| 2013-11-12 | 6-K | 2013-11-12 | DARAPLADIB PHASE III STUDY RESULTS | gsk201311126k.htm |
| 2013-11-12 | 6-K | 2013-11-11 | DIRECTOR/PDMR SHAREHOLDING | gsk201311116k.htm |
| 2013-11-01 | 6-K | 2013-11-01 | TRANSACTION IN OWN SHARES | gsk201311016k2.htm |
| 2013-11-01 | 6-K | 2013-11-01 | TOTAL VOTING RIGHTS | gsk201311016k.htm |
| 2013-10-31 | 6-K | 2013-10-31 | TRANSACTION IN OWN SHARES | gsk201310316k.htm |
| 2013-10-30 | 6-K | 2013-10-31 | TRANSACTION IN OWN SHARES | gsk201310306k.htm |
| 2013-10-28 | 6-K | 2013-10-28 | TRANSACTION IN OWN SHARES | gsk201310286k1.htm |
| 2013-10-28 | 6-K | 2013-10-28 | DIRECTOR/PDMR SHAREHOLDING | gsk201310286k.htm |
| 2013-10-25 | 6-K | 2013-10-25 | TRANSACTION IN OWN SHARES | gsk201310256k3.htm |
| 2013-10-25 | 6-K | 2013-10-25 | DIRECTOR/PDMR SHAREHOLDING | gsk201310256k2.htm |
| 2013-10-25 | 6-K | 2013-10-25 | DOLUTEGRAVIR TRII - EU REGULATORY SUBMISSION | gsk201310256k.htm |
| 2013-10-23 | 6-K | 2013-10-23 | 3RD QUARTER RESULTS | gsk201310236k.htm |
| 2013-10-22 | 6-K | 2013-10-22 | US FDA SUBMISSION FOR TIVICAY COMBINATION | gsk201310226k1.htm |
| 2013-10-22 | 6-K | 2013-10-22 | TRANSACTION IN OWN SHARES | gsk201310226k.htm |
| 2013-10-21 | 6-K | 2013-10-21 | TRANSACTION IN OWN SHARES | gsk201310216k.htm |
| 2013-10-18 | 6-K | 2013-10-18 | TRANSACTION IN OWN SHARES | gsk201310186k.htm |
| 2013-10-17 | 6-K | 2013-10-17 | TRANSACTION IN OWN SHARES | gsk201310176k.htm |
| 2013-10-16 | 6-K | 2013-10-14 | TRANSACTION IN OWN SHARES | gsk201310166k.htm |
| 2013-10-15 | 6-K | 2013-10-14 | TRANSACTION IN OWN SHARES | gsk201310156k1.htm |
| 2013-10-15 | 6-K | 2013-10-15 | ADDITIONAL LISTING | gsk201310156k.htm |
| 2013-10-15 | 6-K | 2013-10-14 | TRANSACTION IN OWN SHARES | gsk201310146k2.htm |
| 2013-10-15 | 6-K | 2013-10-14 | DIRECTOR/PDMR SHAREHOLDING | gsk201310146k1.htm |
| 2013-10-15 | 6-K | 2013-10-14 | DIRECTOR/PDMR SHAREHOLDING | gsk201310146k.htm |
| 2013-10-11 | 6-K | 2013-10-11 | BOARD COMMITTEE CHANGES | gsk201310116k3.htm |
| 2013-10-11 | 6-K | 2013-10-11 | TRANSACTION IN OWN SHARES | gsk201310116k2.htm |
| 2013-10-11 | 6-K | 2013-10-11 | DIRECTOR/PDMR SHAREHOLDING | gsk201310116k1.htm |
| 2013-10-11 | 6-K | 2013-10-11 | DIRECTOR/PDMR SHAREHOLDING | gsk201310116k.htm |
| 2013-10-10 | 6-K | 2013-10-10 | TRANSACTION IN OWN SHARES | gsk201310106k7.htm |
| 2013-10-10 | 6-K | 2013-10-10 | DIRECTOR/PDMR SHAREHOLDING | gsk201310106k6.htm |
| 2013-10-10 | 6-K | 2013-10-10 | DIRECTOR/PDMR SHAREHOLDING | gsk201310106k5.htm |
| 2013-10-10 | 6-K | 2013-10-10 | DIRECTOR/PDMR SHAREHOLDING | gsk201310106k4.htm |
| 2013-10-10 | 6-K | 2013-10-10 | DIRECTOR/PDMR SHAREHOLDING | gsk201310106k2.htm |
| 2013-10-10 | 6-K | 2013-10-10 | DIRECTOR/PDMR SHAREHOLDING | gsk201310106k3.htm |
| 2013-10-10 | 6-K | 2013-10-10 | DIRECTOR/PDMR SHAREHOLDING | gsk201310106k.htm |
| 2013-10-09 | 6-K | 2013-10-09 | TRANSACTION IN OWN SHARES | gsk201310096k3.htm |
| 2013-10-09 | 6-K | 2013-10-09 | DIRECTOR/PDMR SHAREHOLDING | gsk201310096k1.htm |
| 2013-10-09 | 6-K | 2013-10-09 | DIRECTOR/PDMR SHAREHOLDING | gsk201310096k.htm |
| 2013-10-09 | 6-K | 2013-10-09 | DIRECTOR/PDMR SHAREHOLDING | gsk201310096k2.htm |
| 2013-10-08 | 6-K | 2013-10-08 | TRANSACTION IN OWN SHARES | gsk201310086k.htm |
| 2013-10-08 | 6-K | 2013-10-07 | DIRECTOR/PDMR SHAREHOLDING | gsk201310086k.htm |
| 2013-10-07 | 6-K | 2013-10-03 | DIRECTOR/PDMR SHAREHOLDING | gsk201310076k2.htm |
| 2013-10-07 | 6-K | 2013-10-03 | TRANSACTION IN OWN SHARES | gsk201310076k.htm |
| 2013-10-04 | 6-K | 2013-10-04 | TRANSACTION IN OWN SHARES | gsk201310046k3.htm |
| 2013-10-04 | 6-K | 2013-10-04 | DIRECTOR/PDMR SHAREHOLDING | gsk201310046k2.htm |
| 2013-10-04 | 6-K | 2013-10-04 | DIRECTOR/PDMR SHAREHOLDING | gsk201310046k1.htm |
| 2013-10-04 | 6-K | 2013-10-04 | DIRECTOR/PDMR SHAREHOLDING | gsk201310046k.htm |
| 2013-10-03 | 6-K | 2013-10-03 | TRANSACTION IN OWN SHARES | gsk201310036k.htm |
| 2013-10-02 | 6-K | 2013-10-02 | TRANSACTION IN OWN SHARES | gsk201310026k.htm |
| 2013-10-01 | 6-K | 2013-10-01 | TRANSACTION IN OWN SHARES | gsk201310016k4.htm |
| 2013-10-01 | 6-K | 2013-10-01 | DIRECTOR/PDMR SHAREHOLDING | gsk201310016k3.htm |
| 2013-10-01 | 6-K | 2013-10-01 | TOTAL VOTING RIGHTS | gsk201310016k2.htm |
| 2013-10-01 | 6-K | 2013-10-01 | DIRECTOR/PDMR SHAREHOLDING | gsk201310016k.htm |
| 2013-09-30 | 6-K | 2013-09-30 | TRANSACTION IN OWN SHARES | gsk201309306k3.htm |
| 2013-09-30 | 6-K | 2013-09-30 | SHARE BUY-BACK PROGRAMME DURING CLOSE PERIOD | gsk201309306k2.htm |
| 2013-09-30 | 6-K | 2013-09-30 | DIRECTOR/PDMR SHAREHOLDING | gsk201309306k1.htm |
| 2013-09-30 | 6-K | 2013-09-30 | GSK TO DIVEST THROMBOSIS BRANDS AND RELATED SITE | gsk201309306k.htm |
| 2013-09-27 | 6-K | 2013-09-27 | TRANSACTION IN OWN SHARES | gsk201309276k.htm |
| 2013-09-26 | 6-K | 2013-09-26 | TRANSACTION IN OWN SHARES | gsk201309266k.htm |
| 2013-09-25 | 6-K | 2013-09-25 | TRANSACTION IN OWN SHARES | gsk201309256k.htm |
| 2013-09-24 | 6-K | 2013-09-24 | TRANSACTION IN OWN SHARES | gsk201309246k.htm |
| 2013-09-23 | 6-K | 2013-09-23 | TRANSACTION IN OWN SHARES | gsk201309236k.htm |
| 2013-09-20 | 6-K | 2013-09-20 | TRANSACTION IN OWN SHARES | gsk201309206k2.htm |
| 2013-09-20 | 6-K | 2013-09-20 | DIRECTOR/PDMR SHAREHOLDING | gsk201309206k.htm |
| 2013-09-19 | 6-K | 2013-09-19 | RELVAR ELLIPTA CHMP POSITIVE OPINION | gsk201309196k.htm |